Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8544469 | 0.81 | ALDH1A1 (0.45) | ALDH1A1POLBSMN1; SMN2KDM4ETDP1 | |
| SCHEMBL4142245 | 0.80 | ALDH1A1 (0.47) | ALDH1A1POLBSMN1; SMN2KDM4ETDP1 | |
| SCHEMBL12473807 | 0.72 | ALDH1A1 (0.41) | ALDH1A1POLBSMN1; SMN2KDM4ETDP1 | |
| SCHEMBL16470484 | 0.72 | KMT2A (0.41) | ALDH1A1SMN1; SMN2KDM4ELMNAKMT2A | |
| SCHEMBL4537418 | 0.71 | ALDH1A1 (0.39) | ALDH1A1POLBSMN1; SMN2KDM4ETDP1 | |
| SCHEMBL4292571 | 0.70 | ALDH1A1 (0.39) | ALDH1A1POLBSMN1; SMN2HPGDKMT2A | |
| SCHEMBL27710866 | 0.69 | KMT2A (0.36) | ALDH1A1POLBSMN1; SMN2KDM4ELMNA | |
| SCHEMBL28026626 | 0.68 | ALDH1A1 (0.42) | ALDH1A1POLBSMN1; SMN2KDM4ETDP1 | |
| SCHEMBL18428973 | 0.67 | ALDH1A1 (0.45) | ALDH1A1POLBSMN1; SMN2TDP1LMNA | |
| SCHEMBL8779695 | 0.67 | ALDH1A1 (0.50) | ALDH1A1POLBSMN1; SMN2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403853-B1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2013-08-14 | — | — | EP | claimed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | claimed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | claimed |
| WO-2010100431-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-09-10 | — | — | WO | claimed |
| EP-2403853-B1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010100431-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | ALDH1A1 4193/4885POLB 1441/4885SMN1; SMN2 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.